Sort
40,608 grants matching “prostate cancer”
Adenovirus Replication-Competent Anti-Cancer Vector
$351,283Virrx, Inc · R42 · FY2002 · CA
Project 4: Targeting Genomic Instability in Distinct Subclasses of Prostate Cancer
$351,279Christopher E Barbieri · Weill Medical Coll Of Cornell Univ · P50 · FY2020 · CA
Project 2: Targeting N-Myc and EZH2-driven Castrate Resistant Prostate Cancer
$351,277David S. Rickman · Weill Medical Coll Of Cornell Univ · P50 · FY2020 · CA
Core 2: Recruitment and Retention Shared Resource Core
$351,262Maria Pisu · University Of Alabama At Birmingham · P01 · FY2019 · CA
Serum Antibody Profiling with a Carbohydrate Microarray
$351,252Jeff Gildersleeve · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Phosphoinositide 3-Kinase Assays in Cancer Diagnosis
$351,246Echelon Biosciences, Inc. · R44 · FY2003 · CA
Novel targeted chemo/immunotherapy approach for localized and metastatic CaP
$351,227Mohammad Saleem Bhat · University Of Minnesota · R01 · FY2016 · CA
TARGETING THE ANDROGEN RECEPTOR SPLICE VARIANT 7 IN CASTRATION-RESISTANT PROSTATE CANCER
$351,226Dana-Farber Cancer Institute, Inc. · · FY2019 · Department of the Army
Deciphering the function of the APE2 nuclease during repair by alternative end-joining and its role in HR-deficient cells
$351,183Nausica C. Arnoult · University Of Colorado · R01 · FY2025 · CA
Real-time prostate lesion tracking during SBRT
$351,181Jing Wang · Ut Southwestern Medical Center · R01 · FY2022 · EB
Real-time prostate lesion tracking during SBRT
$351,181Jing Wang · Ut Southwestern Medical Center · R01 · FY2020 · EB
Chemical Glycoproteomics
$351,178Carolyn R Bertozzi · Stanford University · R01 · FY2016 · CA
Project 1: Non-Invasive Clinical Assay for Early Detection of Treatment Resistance in Patients with Metastatic Prostate Cancer
$351,178Himisha Beltran · Weill Medical Coll Of Cornell Univ · P50 · FY2020 · CA
PTEN and ontogenesis and tumor suppression
$351,147Pier Paolo Pandolfi · Beth Israel Deaconess Medical Center · R01 · FY2010 · CA
PTEN and ontogenesis and tumor suppression
$351,147Pier Paolo Pandolfi · Beth Israel Deaconess Medical Center · R01 · FY2009 · CA
Novel Mechanisms of ROS/RNS Signaling Underlying Castration-Resistant Prostate Cancer Emergence and Progression
$351,131Priyamvada Rai · University Of Miami School Of Medicine · R01 · FY2020 · CA
Countering microtubule stabilization within hair follicles in ovarian cancer chemotherapy
$351,131Xiangxi Mike Xu · University Of Miami School Of Medicine · R01 · FY2024 · CA
Novel Mechanisms of ROS/RNS Signaling Underlying Castration-Resistant Prostate Cancer Emergence and Progression
$351,131Priyamvada Rai · University Of Miami School Of Medicine · R01 · FY2021 · CA
Countering microtubule stabilization within hair follicles in ovarian cancer chemotherapy
$351,131Xiangxi Mike Xu · University Of Miami School Of Medicine · R01 · FY2025 · CA
Prostate Needle Biopsies: Impact of Preanalytical Procurement and Processing Variables on the Detection of Gene Expression Signatures of Prostate Cancer Aggressiveness
$351,131Alan Pollack · University Of Miami School Of Medicine · U01 · FY2022 · CA
Prostate Needle Biopsies: Impact of Preanalytical Procurement and Processing Variables on the Detection of Gene Expression Signatures of Prostate Cancer Aggressiveness
$351,131Alan Pollack · University Of Miami School Of Medicine · U01 · FY2025 · CA
Leveraging PMN immune response to overcome ADT resistance in bone metastatic prostate cancer
$351,131Leah Marie Cook · University Of Nebraska Medical Center · R01 · FY2022 · CA
CYP17A1-independent androgen synthesis and prostate cancer resistance to next-generation hormonal therapy
$351,131Nima Sharifi · University Of Miami School Of Medicine · R01 · FY2025 · CA
PDGF D and Prostate Cancer Bone Metastasis
$351,130Hyeong-Reh Choi Kim · Wayne State University · R01 · FY2018 · CA
ONLINE CANCER EDUCATION FOR HEALTH CARE PROVIDERS
$351,097Medical Directions, Inc. · R44 · FY2000 · CA